Table 2. Demographic and other details of PHANTASTIC and control patients.
| PHANTASTIC | Control | ||
|---|---|---|---|
| Number of cases | 98 | 151 | |
| Sex (M/F) | 60/38 | 92/59 | |
| Median age (years) | 56 | 55 | |
| Range | 20–68 | 19–70 | |
| Underlying diagnosis | |||
| Myeloma | 45 (46) | 76 (50) | |
| NHL | 39 (40) | 59 (39) | |
| Hodgkins disease | 14 (14) | 16 (11) | |
| Prior treatment | |||
| Original score (median) | 38 | 40 | P=NS |
| Simplified Liverpool score (median) | 14 | 11.5 | P=NS |
| No. of courses (median) | 2 | 2 | |
| No. of cycles (median) | 8 | 7 | |
| Mobilising chemotherapy | |||
| Cyclophosphamide (1.5 gm/m2) | 89 (59) | ||
| ESHAP | 10 (7) | ||
| Post DHAP/R-DHAP | 26 (17) | ||
| Post ICE/R-ICE | 15 (10) | ||
| Post IVE/R-IVE | 9 (6) | ||
| IDARAM/high dose cytarabine | 2 (1) | ||
Abbreviations: ESHAP, etoposide, prednisolone, high dose cytosine arabinoside and procarbazine; DHAP, DTIC (dacarbazine), adriamycin, ara-C and prednisolone; ICE, ifosphamide, carmustine and etoposide; IVE, ifosfamide, etoposide and epirubicin; NHL, non-Hodgkin lymphoma; NS, not significant; R-DHAP, DHAP+rituximab; R-ICE, ICE+rituximab; R-IVE, IVE+rituximab.
Figures in parentheses are percentages. All the control myeloma patients received cyclophosphamide mobilisation, as did 10 lymphoma patients. The other mobilisation regimes were exclusively used in lymphoma patients; their component drugs are given in Table 1.